LANSOPRAZOLE; NAPROXEN - Generic Drug Details

What are the generic drug sources for lansoprazole; naproxen and what is the scope of patent protection?

Lansoprazole; naproxen is the generic ingredient in three branded drugs marketed by Takeda Pharms Na and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for LANSOPRAZOLE; NAPROXEN

US Patents:	0
Tradenames:	3
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	LANSOPRAZOLE; NAPROXEN at DailyMed

Recent Clinical Trials for LANSOPRAZOLE; NAPROXEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4
Takeda	Phase 2

See all LANSOPRAZOLE; NAPROXEN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for LANSOPRAZOLE; NAPROXEN

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

G02CC	Antiinflammatory products for vaginal administration
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

M01AE	Propionic acid derivatives
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

US Patents and Regulatory Information for LANSOPRAZOLE; NAPROXEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Na	PREVACID NAPRAPAC 250 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-002	Nov 14, 2003		DISCN	Yes	No
Takeda Pharms Na	PREVACID NAPRAPAC 375 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-003	Nov 14, 2003		DISCN	No	No
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003		DISCN	No	No

Expired US Patents for LANSOPRAZOLE; NAPROXEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003

LANSOPRAZOLE; NAPROXEN Market Analysis and Financial Projection

Last updated: February 13, 2026

What are the current market dynamics for Lansoprazole and Naproxen?

Lansoprazole and Naproxen are both well-established pharmaceuticals with distinct market profiles. Lansoprazole, a proton pump inhibitor (PPI), targets gastrointestinal conditions, while Naproxen, a non-steroidal anti-inflammatory drug (NSAID), addresses pain and inflammation.

Market Size and Growth Trends

• Global Proton Pump Inhibitors Market (including Lansoprazole): Valued at approximately $10.7 billion in 2021, projected to grow at a CAGR of 4.1% through 2028 [1].
• Global NSAIDs Market (including Naproxen): Estimated at $17 billion in 2022, with a CAGR of 3.9% forecasted until 2027 [2].

Key Drivers

• Rising prevalence of GERD, acid reflux, and ulcerative diseases propels PPI demand.
• Increasing incidence of osteoarthritis, rheumatoid arthritis, and musculoskeletal pain supports NSAID use.
• Growing aging populations contribute to sustained demand for both drugs.

Competitive Landscape

• Lansoprazole is marketed by multiple companies, including Takeda and Mylan, along with generics.
• Naproxen faces competition from ibuprofen, diclofenac, and celecoxib, with several manufacturers producing over-the-counter and prescription formulations.

Regulatory Environment

• Both drugs are off-patent, leading to high generic penetration.
• New formulations or delivery methods face regulatory scrutiny but generally do not hinder market access.

Market Challenges

• Safety concerns: Long-term PPI use links to nutrient deficiencies and infection risks; NSAID-related gastrointestinal and cardiovascular adverse effects pose safety concerns.
• Pricing pressures from generics reduce profit margins.

Geographic Variations

• North America: Largest markets due to high prevalence of GI and musculoskeletal conditions.
• Asia-Pacific: Rapid growth driven by expanding healthcare infrastructure and prevalence rates.

---

How are the financial trajectories shaping for Lansoprazole and Naproxen?

Revenue Trends

Drug	2018 Revenue	2021 Revenue	2023 Estimate	CAGR (2018-23)
Lansoprazole	$1.2B (generic)	$1.3B (generic)	$1.3B	0.7%
Naproxen	$900M (generic)	$950M	$960M	0.7%

(Note: Revenue estimates include global sales, predominantly generics.)

Profitability Outlook

• Margins are flattening due to rising competition and pricing pressures.
• Branded versions, where still marketed, report higher margins but face rapid erosion upon patent expiry.

R&D and Pipeline Investment

• Minimal R&D focus, as both drugs are off-patent.
• Future value hinges on formulation innovations, such as new delivery systems and combination therapies.

Impact of Biosimilars and Generics

• The market share of generic Lansoprazole and Naproxen increases annually.
• Price erosion in major markets, such as the U.S. and Europe, averages 4-6% per year post-patent loss.

Future Financial Drivers

• Pharma companies shift focus from core formulations to additional indications or novel formulations.
• Potential growth areas include OTC expansion and combination therapies for NPD (non-pharmacological drug development).

---

What are the risks affecting the market outlook?

• Evolving safety regulations can restrict prescribing or prompt reformulations.
• Litigation risks related to adverse effect claims can mean added costs.
• Market saturation in developed regions constrains growth.
• Emerging markets potentially offer growth but face access and regulatory challenges.

---

Key Takeaways

• Both Lansoprazole and Naproxen are mature markets dominated by generic manufacturers.
• Market growth remains modest at best, driven by aging populations and rising disease prevalence.
• Price erosion due to generics and safety concerns limit profit margins.
• Innovative delivery or combination therapies could offer some revenue growth but are currently limited.
• Regional drivers concentrate in North America and Asia-Pacific markets.

---

FAQs

Q1: Are there any new formulations for Lansoprazole or Naproxen in development?
Limited pipeline activity exists; most innovations focus on delivery methods, such as extended-release formulations, but none are expected to significantly alter market dynamics soon.

Q2: How does patent expiration impact profits for these drugs?
Patent expiration leads to generic entry, reducing prices by 50% or more within two years, which compresses margins for originators.

Q3: Are there any regulatory hurdles specific to Lansoprazole and Naproxen?
Both drugs face standard safety and efficacy assessments; no major regulatory hurdles are currently reported, but safety concerns influence prescribing patterns.

Q4: What is the outlook for over-the-counter sales?
Growing availability of both drugs OTC in many markets supports revenue, especially for Naproxen, but may also intensify price competition.

Q5: How do safety concerns influence market growth?
Adverse effects tied to long-term use may limit prescriptions and push patients toward alternative therapies, capping growth potential.

---

References

[1] Grand View Research, "Proton Pump Inhibitors Market," 2022.
[2] Fortune Business Insights, "NSAIDs Market," 2022.